Oxigene terminates its $40 million committed equity financing facility

Agreement with Kingsbridge Capital was negotiated on Feb. 19, 2008

By Devika Patel

Knoxville, Tenn., Oct. 14 - Oxigene Inc. terminated a $40 million committed equity financing facility on Oct. 14, according to an 8-K filed Friday with the Securities and Exchange Commission. The agreement was negotiated with Kingsbridge Capital Ltd. on Feb. 19, 2008.

Oxigene had issued a warrant to Kingsbridge in connection with the agreement. The warrant, for 12,500 shares, remains exercisable until Aug. 19, 2013.

Oxigene is a pharmaceutical company located in South San Francisco.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.